Capital Fund Management S.A. Acquires Shares of 101,406 Travere Therapeutics, Inc. $TVTX

Capital Fund Management S.A. bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 101,406 shares of the company’s stock, valued at approximately $1,501,000. Capital Fund Management S.A. owned about 0.11% of Travere Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in Travere Therapeutics during the first quarter worth $62,000. Atria Investments Inc bought a new position in Travere Therapeutics in the 2nd quarter valued at $154,000. Corton Capital Inc. purchased a new stake in shares of Travere Therapeutics during the 2nd quarter valued at $159,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Travere Therapeutics during the 2nd quarter valued at $241,000. Finally, E Fund Management Co. Ltd. raised its stake in shares of Travere Therapeutics by 8.6% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,553 shares of the company’s stock worth $243,000 after purchasing an additional 1,072 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on TVTX shares. TD Cowen increased their price target on shares of Travere Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Piper Sandler increased their target price on shares of Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Cowen reaffirmed a “buy” rating on shares of Travere Therapeutics in a report on Friday, October 31st. Stifel Nicolaus upped their price objective on Travere Therapeutics from $20.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, September 12th. Finally, Wedbush raised their target price on Travere Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $38.71.

Insider Buying and Selling

In other Travere Therapeutics news, CAO Sandra Calvin sold 67,115 shares of the firm’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the transaction, the chief accounting officer owned 48,545 shares in the company, valued at $1,747,620. This trade represents a 58.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric M. Dube sold 92,872 shares of Travere Therapeutics stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.38, for a total value of $2,821,451.36. Following the transaction, the chief executive officer directly owned 419,173 shares of the company’s stock, valued at $12,734,475.74. The trade was a 18.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 243,368 shares of company stock valued at $7,910,972 in the last 90 days. Corporate insiders own 4.19% of the company’s stock.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $35.33 on Friday. The firm’s 50 day moving average is $30.85 and its 200 day moving average is $22.05. The stock has a market capitalization of $3.16 billion, a P/E ratio of -33.33 and a beta of 0.89. Travere Therapeutics, Inc. has a 12 month low of $12.91 and a 12 month high of $37.50. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The business had revenue of $164.86 million during the quarter, compared to analyst estimates of $106.09 million. During the same period in the previous year, the business earned ($0.70) EPS. Travere Therapeutics’s revenue was up 162.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.